

1. Dao, V., Pandeswara, S., Liu, Y., Hurez, V., Dodds, S., Callaway, D., Liu, A., Hasty, P., Sharp, Z. D., and Curiel, T. J. (2015) Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. *Cancer Prev Res (Phila)* **8**, 400-409
2. Hurez, V., Dao, V., Liu, A., Pandeswara, S., Gelfond, J., Sun, L., Bergman, M., Orihuela, C. J., Galvan, V., Padron, A., Drerup, J., Liu, Y., Hasty, P., Sharp, Z. D., and Curiel, T. J. (2015) Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. *Aging Cell* **14**, 945-956
3. Gajewski, T. F., Schreiber, H., and Fu, Y. X. (2013) Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* **14**, 1014-1022
4. Zou, W., and Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol* **8**, 467-477
5. Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., Sayegh, M. H., Blazar, B. R., Freeman, G. J., and Sharpe, A. H. (2011) The programmed death-1 ligand 1:b7-1 pathway restrains diabetogenic effector T cells in vivo. *J Immunol* **187**, 1097-1105
6. Topalian, S. L., Drake, C. G., and Pardoll, D. M. (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* **24**, 207-212
7. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., Lennon, V. A., Celis, E., and Chen, L. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. *Nat Med* **8**, 793-800.
8. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthi, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A., and Wigginton, J. M. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* **366**, 2455-2465
9. Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., and Chen, L. (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med* **4**, 127ra137
10. Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* **12**, 252-264
11. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., and Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* **366**, 2443-2454
12. Sunshine, J., and Taube, J. M. (2015) PD-1/PD-L1 inhibitors. *Curr Opin Pharmacol* **23**, 32-38
13. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R. D., Emilie, D., Curiel, D. T., Chen, L., and Zou, W. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nat Med* **9**, 562-567
14. Habicht, A., Dada, S., Jurewicz, M., Fife, B. T., Yagita, H., Azuma, M., Sayegh, M. H., and Guleria, I. (2007) A link between PDL1 and T regulatory cells in fetomaternal tolerance. *J Immunol* **179**, 5211-5219
15. Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., and Sharpe, A. H. (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med*
16. Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., Kohrt, H. E., Horn, L., Lawrence, D. P., Rost, S., Leabman, M., Xiao, Y., Mokatrini, A., Koeppen, H., Hegde, P. S., Mellman, I., Chen, D. S., and Hodi, F. S. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* **515**, 563-567
17. Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., O'Donnell, P. H., Drakaki, A., Tan, W., Kurland, J. F., Rebelatto, M. C., Jin, X., Blake-Haskins, J. A., Gupta, A., and Segal, N. H. (2016) Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *J Clin Oncol*
18. Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., and Chen, L. (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. *Blood* **111**, 3635-3643
19. Orzechowski, A., and Dong, H. (2014) B7-H1 confers tumor chemoresistance by regulating MAPK/ERK activation. *Cancer Research* **74**, abstract 5026

20. Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., and Gajewski, T. F. (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med* **5**, 200ra116
21. Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., and Hersey, P. (2015) Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. *PLoS One* **10**, e0123410
22. Spranger, S., Bao, R., and Gajewski, T. F. (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature*
23. Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., Lian, C. G., Thomi, R., Hoetzenecker, W., Cozzio, A., Dummer, R., Mihm, M. C., Jr., Flaherty, K. T., Frank, M. H., Murphy, G. F., Sharpe, A. H., Kupper, T. S., and Schatton, T. (2015) Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. *Cell* **162**, 1242-1256
24. Lin, P. Y., Sun, L., Thibodeaux, S. R., Ludwig, S. M., Vadlamudi, R. K., Hurez, V. J., Bahar, R., Kious, M. J., Livi, C. B., Wall, S. R., Chen, L., Zhang, B., Shin, T., and Curiel, T. J. (2010) B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. *J Immunol* **185**, 2747-2753
25. Steinberg, S. M., Zhang, P., Malik, B. T., Boni, A., Shabaneh, T. B., Byrne, K. T., Mullins, D. W., Brinckerhoff, C. E., Ernstoff, M. S., Bosenberg, M. W., and Turk, M. J. (2014) BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. *Cancer immunology research* **2**, 1044-1050
26. Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr., You, M. J., DePinho, R. A., McMahon, M., and Bosenberg, M. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* **41**, 544-552
27. Drerup, J., A. Liu, Hurez, V., and Curiel, T. J. (2015) Anti-CD25 antibody and denileukin diftitox deplete regulatory T cells in ID8 ovarian cancer equally, but α CD25 promotes more T cell cytotoxicity that correlates with better survival (VAC12P.1112). *The Journal of Immunology* **194**, 213.213
28. Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., and Coukos, G. (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. *Nat Med* **14**, 28-36
29. Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gassel, I., Gordon, A., Pustilnik, T., Curiel, D. T., Galanaud, P., Capron, F., Emilie, D., and Curiel, T. J. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. *Nat Med* **7**, 1339-1346.
30. Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., Ranta, F., Ullrich, S., Mocikat, R., Braungart, K., Mehra, T., Fehrenbacher, B., Berdel, J., Niessner, H., Meier, F., van den Broek, M., Haring, H. U., Handgretinger, R., Quintanilla-Martinez, L., Fend, F., Pesic, M., Bauer, J., Zender, L., Schaller, M., Schulze-Osthoff, K., and Rocken, M. (2013) T-helper-1-cell cytokines drive cancer into senescence. *Nature* **494**, 361-365
31. Fujigaki, H., Saito, K., Fujigaki, S., Takemura, M., Sudo, K., Ishiguro, H., and Seishima, M. (2006) The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. *J Biochem* **139**, 655-662
32. Lucas, D. M., Lokuta, M. A., McDowell, M. A., Doan, J. E., and Paulnock, D. M. (1998) Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation. *J Immunol* **160**, 4337-4342
33. Karin, M. (2009) NF-kappaB as a critical link between inflammation and cancer. *Cold Spring Harbor perspectives in biology* **1**, a000141
34. Jenkins, M. H., Steinberg, S. M., Alexander, M. P., Fisher, J. L., Ernstoff, M. S., Turk, M. J., Mullins, D. W., and Brinckerhoff, C. E. (2014) Multiple murine BRAf(V600E) melanoma cell lines with sensitivity to PLX4032. *Pigment cell & melanoma research* **27**, 495-501
35. Denkers, E. Y., Gazzinelli, R. T., Martin, D., and Sher, A. (1993) Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. *J Exp Med* **178**, 1465-1472
36. Curiel, T., Murthy, K., Kious, M., Sun, L., Zhang, B., Pandaswara, S., and Hurez, V. (2013) B7-H1 blockade plus regulatory T cell depletion improves clinical efficacy over either strategy alone in a melanoma model (P4268). *The Journal of Immunology* **190**, 140.144

37. Murthy, K., Kiouis, M., Hurez, V., Pandeswara, S., Zhang, B., Sun, L., and Curiel, T. J. (2013) B7-H1 blockade plus regulatory T cell depletion improves anti-tumor immunity and clinical efficacy over either agent alone in a melanoma model. *American Association of Immunologists 2013 Meeting*
38. Dao, V., Hurez, V., Pandeswara, S. L., Cardenas, K., Sun, L., Liu, A., Hasty, P., Sharp, Z. D., and Curiel, T. (2014) Oral rapamycin (eRapa) safely prevents carcinogen-induced dermal carcinogenesis through an interferon- γ -dependent mechanism (TUM7P.931). *The Journal of Immunology* **192**, 203.213
39. Dao, V., Pandeswara, S. L., Hurez, V., Dodds, S., Liu, Y., Liu, A., Sharp, Z. D., Hasty, R. P., and Curiel, T. J. (2014) Oral rapamycin prevents carcinogen and inflammation-induced dermal carcinogenesis through immune and DNA damage mechanisms *2014 International Cytokine and Interferon Society, Melbourne Australia*
40. Castriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F., Conte, R., Corrias, M. V., Moretta, L., Moretta, A., and Bottino, C. (2004) Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. *Proc Natl Acad Sci U S A* **101**, 12640-12645
41. Xu, H., Cheung, I. Y., Guo, H. F., and Cheung, N. K. (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. *Cancer Res* **69**, 6275-6281
42. Narni-Mancinelli, E., Chaix, J., Fenis, A., Kerdiles, Y. M., Yessaad, N., Reynders, A., Gregoire, C., Luche, H., Ugolini, S., Tomasello, E., Walzer, T., and Vivier, E. (2011) Fate mapping analysis of lymphoid cells expressing the Nkp46 cell surface receptor. *Proc Natl Acad Sci U S A* **108**, 18324-18329
43. Wan, Y. Y., and Flavell, R. A. (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. *Nature* **445**, 766-770
44. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., and Zou, W. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* **10**, 942-949
45. Hurez, V., Daniel, B. J., Sun, L., Liu, A. J., Ludwig, S. M., Kiouis, M. J., Thibodeaux, S. R., Pandeswara, S., Murthy, K., Livi, C. B., Wall, S., Brumlik, M. J., Shin, T., Zhang, B., and Curiel, T. J. (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. *Cancer Res* **72**, 2089-2099
46. Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., Singhal, S., Albelda, S. M., Granot, Z., and Fridlender, Z. G. (2014) Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. *Int J Cancer* **135**, 1178-1186
47. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., and Coukos, G. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature* **475**, 226-230
48. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., Long, G. V., Callahan, M. K., Postow, M. A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L. M., Horak, C., Hodi, F. S., and Wolchok, J. D. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* **373**, 23-34
49. Figueiredo, A. S. P., Hurez, V., Liu, A., and 2016, T. J. C. J. I. (2016) Age and sex affect α CTLA-4 efficacy alone and combined with α B7-H1 or regulatory T cell depletion in a melanoma model. *Journal of Immunology* **196**, 213.214
50. Scanduzzi, L., Ghosh, K., Hofmeyer, K. A., Abadi, Y. M., Lazar-Molnar, E., Lin, E. Y., Liu, Q., Jeon, H., Almo, S. C., Chen, L., Nathanson, S. G., and Zang, X. (2014) Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. *Cell reports*
51. Cardenas, K., Dao, V., Hurez, V., and Curiel, T. (2014) Age-related gut dysbiosis contributes to age-related colitis and colon cancer risk and appears B7-H1-dependent. (HUM8P.352). *The Journal of Immunology* **192**, 185.127
52. Viaud, S., Daillere, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., and Zitvogel, L. (2015) Gut microbiome and anticancer immune response: really hot Sh*t! *Cell Death Differ* **22**, 199-214
53. Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M. L., Chang, E. B., and Gajewski, T. F. (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* **350**, 1084-1089

54. Naing, A., Aghajanian, C., Raymond, E., Olmos, D., Schwartz, G., Oelmann, E., Grinsted, L., Burke, W., Taylor, R., Kaye, S., Kurzrock, R., and Banerji, U. (2012) Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. *Br J Cancer* **107**, 1093-1099
55. Lastwika, K. J., Wilson, W., 3rd, Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., and Dennis, P. A. (2016) Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. *Cancer Res* **76**, 227-238
56. Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gutgemann, I., Eilers, M., and Felsher, D. W. (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. *Science* **352**, 227-231
57. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., and Freeman, G. J. (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity* **27**, 111-122
58. Wang, J. W., Wang, A., Li, K., Wang, B., Jin, S., Reiser, M., and Lockey, R. F. (2015) CRISPR/Cas9 nuclease cleavage combined with Gibson assembly for seamless cloning. *Biotechniques* **58**, 161-170
59. Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., and Chen, L. (2003) Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. *J Exp Med* **197**, 1083-1091
60. Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., and Zhang, B. (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. *J Clin Invest* **121**, 2371-2382
61. Whipple, C. A., Boni, A., Fisher, J. L., Hampton, T. H., Tsongalis, G. J., Mellinger, D. L., Yan, S., Tafe, L. J., Brinckerhoff, C. E., Turk, M. J., Mullins, D. W., Fadul, C. E., and Ernstoff, M. S. (2016) The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. *Melanoma Res* **26**, 223-235
62. Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., Peng, W., Sullivan, R. J., Lawrence, D. P., Hodi, F. S., Overwijk, W. W., Lizee, G., Murphy, G. F., Hwu, P., Flaherty, K. T., Fisher, D. E., and Wargo, J. A. (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. *Clin Cancer Res* **19**, 1225-1231
63. Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., Tompers Frederick, D., Cooper, Z. A., Mbofung, R. M., Whittington, M., Flaherty, K. T., Woodman, S. E., Davies, M. A., Radvanyi, L. G., Overwijk, W. W., Lizee, G., and Hwu, P. (2013) BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. *Clin Cancer Res* **19**, 393-403
64. Steinberg, S. M., and Turk, M. J. (2015) BRAF-inhibition and tumor immune suppression. *Oncoimmunology* **4**, e988039
65. Donia, M., Larsen, S. M., Met, O., and Svane, I. M. (2014) Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. *Cytotherapy* **16**, 1117-1120